Clinical management of community acquired pneumonia in the elderly patient

Expert Review of Respiratory Medicine

Volumn 10, Issue 11, 2016, Pages 1211-1220

  Cilloniz, Catia ^a   Ceccato, Adrian ^b   San Jose, Alicia ^a   Torres, Antoni ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

Author keywords

Community acquired pneumonia; elderly; pneumonia

Indexed keywords

PNEUMOCOCCUS VACCINE;

AGING; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; EPIDEMIOLOGICAL DATA; HOSPITAL PATIENT; HUMAN; IMMUNE SYSTEM; INCIDENCE; INFLUENZA VACCINATION; MORTALITY RATE; NONHUMAN; PROGNOSIS; REVIEW; VULNERABLE POPULATION;

EID: 84992047501     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1080/17476348.2016.1240037     Document Type: Review

References (75)

1. L.A.Mandell, R.G.Wunderink, A.Anzueto, et al. Infectious diseases society of America/American Thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72.•• Important concensus of United States of management of CAP.
2. T.P.Quan, N.J.Fawcett, J.M.Wrightson, et al. Increasing burden of community-acquired pneumonia leading to hospitalisation, 1998-2014. Thorax. 2016;71:535–542.
3. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013:a systematic analysis for the Global Burden of Disease study 2013. Lancet. 2015;385:117–171.
4. T.Welte, A.Torres, D.Nathwani Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–79.•• Important article about economic burden of CAP.
5. C.Cilloniz, E.Polverino, S.Ewig, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest. 2013;144:999–1007.•• Important article about the influence of age and comorbidities on outcomes of CAP.
6. O.Ochoa-Gondar, A.Vila-Corcoles, D.C.de, et al. The burden of community-acquired pneumonia in the elderly:the Spanish EVAN-65 study. BMC Public Health. 2008;8:222.
7. A.Vila-Corcoles, O.Ochoa-Gondar, T.Rodriguez-Blanco, et al. Epidemiology of community-acquired pneumonia in older adults:a population-based study. Respir Med. 2009;103:309–316.
8. V.Kaplan, D.C.Angus, M.F.Griffin, et al. Hospitalized community-acquired pneumonia in the elderly:age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med. 2002;165:766–772.
9. D.P.Speert. Bacterial infections of the lung in normal and immunodeficient patients. Novartis Found Symp. 2006;279:42–51.
10. D.Weiskopf, B.Weinberger, B.Grubeck-Loebenstein. The aging of the immune system. Transpl Int. 2009;22:1041–1050.
11. J.P.Janssens. Pneumonia in the elderly (geriatric) population. Curr Opin Pulm Med. 2005;11:226–230.
12. United Nations Department of Economic and Social Affairs/Population Division. World population prospects:the 2015 revision volume II:Demographic Profiles. 2015. Ref Type:Report
13. S.Jain, W.H.Self, R.G.Wunderink, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373:415–427.• Important article about microbial etiology of CAP.
14. S.Ewig, N.Birkner, R.Strauss, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009;64:1062–1069.
15. M.H.Rozenbaum, M.J.Mangen, S.M.Huijts, et al. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia:A nationwide retrospective claims database analysis. Vaccine. 2015;33:3193–3199.
16. H.H.Klausen, J.Petersen, T.Lindhardt, et al. Outcomes in elderly Danish citizens admitted with community-acquired pneumonia. Regional differencties, in a public healthcare system. Respir Med. 2012;106:1778–1787.
17. D.T.Eurich, T.J.Marrie, J.K.Minhas-Sandhu, et al. Ten-year mortality after community-acquired pneumonia. A prospective cohort. Am J Respir Crit Care Med. 2015;192:597–604.
18. C.M.Luna, I.Palma, M.S.Niederman, et al. The impact of age and comorbidities on the mortality of patients of different age groups admitted with community-acquired pneumonia. Ann Am Thorac Soc. 2016;13:1519–1526.•• Important article about influence of comorbidities on CAP.
19. D.P.Kofteridis, G.Giourgouli, M.N.Plataki, et al. Community-acquired pneumonia in elderly adults with type 2 diabetes mellitus. J Am Geriatr Soc. 2016;64:649–651.
20. M.L.Jackson, J.C.Nelson, L.A.Jackson. Risk factors for community-acquired pneumonia in immunocompetent seniors. J Am Geriatr Soc. 2009;57:882–888.
21. E.Polverino, P.Dambrava, C.Cilloniz, et al. Nursing home-acquired pneumonia:a 10 year single-centre experience. Thorax. 2010;65:354–359.
22. A.A.El Solh, P.Sikka, F.Ramadan, et al. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med. 2001;163:645–651.
23. R.L.Sherwin, S.Gray, R.Alexander, et al. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged >/=50 years with community-acquired pneumonia. J Infect Dis. 2013;208:1813–1820.
24. M.M.Angeles, M.Camps, T.Pumarola, et al. The role of viruses in the aetiology of community-acquired pneumonia in adults. Antivir Ther. 2006;11:351–359.
25. O.G.Rocha Neto, R.F.Leite, B.G.Baldi. Update on viral community-acquired pneumonia. Rev Assoc Med Bras. 2013;59:78–84.
26. M.Burk, K.El-Kersh, M.Saad, et al. Viral infection in community-acquired pneumonia:a systematic review and meta-analysis. Eur Respir Rev. 2016;25:178–188.
27. S.Ewig, B.Klapdor, M.W.Pletz, et al. Nursing-home-acquired pneumonia in Germany:an 8-year prospective multicentre study. Thorax. 2011;67:132–138.
28. C.Cilloniz, A.Gabarrus, M.Ferrer, et al. Community-acquired pneumonia due to multidrug and non-multidrug resistant Pseudomonas aeruginosa. Chest. 2016Apr6;pii:S0012-3692(16)47572-0. [Epub ahead of print] DOI:10.1016/j.chest.2016.03.042.•• Important article about MDR Pseudomona aeruginosa in CAP.
29. E.Prina, O.T.Ranzani, E.Polverino, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. 2015;12:153–160.
30. S.Aliberti, A.M.Zanaboni, F.Blasi. Pneumonia in the community caused by multidrug-resistant organisms:keep working on probabilistic scores. Clin Infect Dis. 2012;54:1519–1520.
31. P.Faverio, S.Aliberti, G.Bellelli, et al. The management of community-acquired pneumonia in the elderly. Eur J Intern Med. 2014;25:312–319.
32. S.K.Basi, T.J.Marrie, J.Q.Huang, et al. Patients admitted to hospital with suspected pneumonia and normal chest radiographs:epidemiology, microbiology, and outcomes. Am J Med. 2004;117:305–311.
33. T.Haga, M.Fukuoka, M.Morita, et al. Computed tomography for the diagnosis and evaluation of the severity of community-acquired pneumonia in the elderly. Intern Med. 2016;55:437–441.
34. A.Ticinesi, F.Lauretani, A.Nouvenne, et al. Lung ultrasound and chest x-ray for detecting pneumonia in an acute geriatric ward. Medicine (Baltimore). 2016;95:e4153.
35. J.Negin, S.Abimbola, B.J.Marais. Tuberculosis among older adults–time to take notice. Int J Infect Dis. 2015;32:135–137.
36. B.C.Mpondo. HIV infection in the elderly:arising challenges. J Aging Res. 2016;2016:2404857.
37. B.G.Demissei, M.A.Valente, J.G.Cleland, et al. Optimizing clinical use of biomarkers in high-risk acute heart failure patients. Eur J Heart Fail. 2016;18:269–280.
38. B.G.Demissei, J.G.Cleland, C.M.O’Connor, et al. Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. Int J Cardiol. 2016;204:164–171.
39. A.Akirov, I.Shimon. The prognostic significance of admission blood glucose levels in elderly patients with pneumonia (GAP study). J Diabetes Complications. 2016;30:845–851.
40. B.Neupane, S.D.Walter, P.Krueger, et al. Predictors of inhospital mortality and re-hospitalization in older adults with community-acquired pneumonia:a prospective cohort study. BMC Geriatr. 2010;10:22.
41. M.J.Fine, T.E.Auble, D.M.Yealy, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–250.
42. W.S.Lim, M.M.van der Eerden, R.Laing, et al. Defining community acquired pneumonia severity on presentation to hospital:an international derivation and validation study. Thorax. 2003;58:377–382.
43. J.H.Chen, S.S.Chang, J.J.Liu, et al. Comparison of clinical characteristics and performance of pneumonia severity score and CURB-65 among younger adults, elderly and very old subjects. Thorax. 2010;65:971–977.
44. P.G.Charles, R.Wolfe, M.Whitby, et al. SMART-COP:a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47:375–384.
45. R.Riquelme, A.Torres, M.El-Ebiary, et al. Community-acquired pneumonia in the elderly. clinical and nutritional aspects. Am J Respir Crit Care Med. 1997;156:1908–1914.
46. R.Zalacain, J.Camino, V.Cabriada. Pneumonia in the elderly. Arch Bronconeumol. 1998;34(Suppl 2):63–67.
47. R.Menendez, A.Torres, R.Zalacain, et al. Risk factors of treatment failure in community acquired pneumonia:implications for disease outcome. Thorax. 2004;59:960–965.
48. M.Woodhead, F.Blasi, S.Ewig, et al. Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiol Infect. 2011;17(Suppl 6):E1–59.
49. E.M.Mortensen, E.A.Halm, M.J.Pugh, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. Jama. 2014;311:2199–2208.
50. L.Asadi, W.I.Sligl, D.T.Eurich, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia:a systematic review and meta-analysis. Clin Infect Dis. 2012;55:371–380.
51. M.I.Restrepo, E.M.Mortensen, G.W.Waterer, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009;33:153–159.
52. A.Kovaleva, H.H.Remmelts, G.T.Rijkers, et al. Immunomodulatory effects of macrolides during community-acquired pneumonia:a literature review. J Antimicrob Chemother. 2012;67:530–540.
53. L.Saiman, M.Anstead, N.Mayer-Hamblett, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa:a randomized controlled trial. JAMA. 2010;303:1707–1715.
54. R.K.Albert, J.Connett, W.C.Bailey, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–698.
55. C.Wong, L.Jayaram, N.Karalus, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE):a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660–667.
56. D.F.Postma, C.H.van Werkhoven, L.J.van Elden, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372:1312–1323.
57. N.Garin, D.Genne, S.Carballo, et al. Beta-lactam monotherapy vs beta-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia:a randomized noninferiority trial. JAMA Intern Med. 2014;174:1894–1901.
58. Y.Shindo, R.Ito, D.Kobayashi, et al. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics:an observational cohort study. Lancet Infect Dis. 2015;15:1055–1065.
59. E.M.Mortensen, B.Nakashima, J.Cornell, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis. 2012;55:1466–1473.
60. S.Shah, E.McArthur, A.Farag, et al. Risk of hospitalization for community acquired pneumonia with renin-angiotensin blockade in elderly patients:a population-based study. PLoS One. 2014;9:e110165.
61. D.Viasus, C.Garcia-Vidal, A.F.Simonetti, et al. The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia:a randomised, double-blind, placebo-controlled trial. BMJ Open. 2015;5:e006251.
62. F.Havers, A.M.Bramley, L.Finelli, et al. Statin use and hospital length of stay among adults hospitalized with community-acquired pneumonia. Clin Infect Dis. 2016;62:1471–1478.
63. A.Torres, O.Sibila, M.Ferrer, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response:a randomized clinical trial. JAMA. 15 A.D. Ref Type:Generic. 2015;313:677–686.• Important article about corticosteroids in CAP.
64. C.A.Blum, N.Nigro, M.Briel, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia:a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385:1511–1518.
65. Y.D.Wan, T.W.Sun, Z.Q.Liu, et al. Efficacy and safety of corticosteroids for community-acquired pneumonia:a systematic review and meta-analysis. Chest. 2016;149:209–219.
66. R.A.Siemieniuk, M.O.Meade, P.onso-Coello, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia:a systematic review and meta-analysis. Ann Intern Med. 2015 Aug 11; [Epub ahead of print] DOI:10.7326/M15-0715.
67. B.Klapdor, S.Ewig, M.W.Pletz, et al. Community-acquired pneumonia in younger patients is an entity on its own. Eur Respir J. 2012;39:1156–1161.
68. V.Kaplan, G.Clermont, M.F.Griffin, et al. Pneumonia:still the old man’s friend? Arch Intern Med. 2003;163:317–323.
69. E.M.Mortensen, W.N.Kapoor, C.C.Chang, et al. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis. 2003;37:1617–1624.
70. J.Johnstone, D.T.Eurich, S.R.Majumdar, et al. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia:a population-based cohort study. Medicine (Baltimore). 2008;87:329–334.
71. H.C.Prescott, M.W.Sjoding, T.J.Iwashyna. Diagnoses of early and late readmissions after hospitalization for pneumonia. A systematic review. Ann Am Thorac Soc. 2014;11:1091–1100.
72. W.S.Lim, S.V.Baudouin, R.C.George, et al. BTS guidelines for the management of community acquired pneumonia in adults:update 2009. Thorax. 2009;64(Suppl 3):iii1–55.•• Importantant European Concensus of management of CAP.
73. M.Kobayashi, N.M.Bennett, R.Gierke, et al. Intervals between PCV13 and PPSV23 vaccines:recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;64:944–947.
74. D.K.Kim, C.B.Bridges, K.H.Harriman. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older–United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:91–92.
75. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions:recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816–819.